Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
RNA interference (RNAi)
Biotech
Arrowhead on target in lipid disorder as it pursues Ionis
Arrowhead linked its RNAi drug candidate to improved outcomes through Week 48 to stay on Ionis’ tail in the race to market.
Nick Paul Taylor
Apr 8, 2024 9:37am
Arrowhead axes assets, but spares staff, to save $100M a year
Feb 7, 2024 6:01am
Alnylam, Biogen build noise in Alzheimer's with gene silencing
Oct 26, 2023 8:51am
Alnylam's RNAi approach to Alzheimer's reaches biomarker target
Jul 17, 2023 2:21am
Arbutus' oral checkpoint inhibitor slapped with clinical hold
Apr 25, 2023 11:00am
Novo Nordisk recruits, lays off staff in Boston expansion
Mar 2, 2023 9:25am